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Abstract 
Background: Hepatitis B virus infection is considered a major 
worldwide public health problem. While adults that acquire acute infection 
usually recover, the chronic type is ultimately fatal both to them and their 
foetuses. In endemic areas, individuals are infected by vertical transmission or 
infection in early childhood. The seroprevalence rates of Hepatitis B in 
pregnancy vary according to the endemicity of a given area with very high 
prevalence rates mostly reported among developing nations in Asia and 
Africa. Objective: To determine the seroprevalence of hepatitis B surface 
antigen  in pregnant women attending the antenatal clinic, identify the clinical 
and epidemiological correlates for hepatitis B in pregnancy and to make 
evidence based recommendations on screening protocols for our obstetric 
population at the Federal Medical Centre, Yenagoa. Methodology: This is a 
descriptive cross sectional study. Two hundred and twenty (220) consecutive 
healthy pregnant women attending the antenatal booking clinic of the hospital 
who met the inclusion criteria were recruited into this study after pretest 
counselling and obtaining consent from them. This was tested for HBsAg with 
commercially available in vitro diagnostic kits (one step test strips). Data was 
collected via a structured interviewer administered questionnaire. Data entry 
and analysis was done using SPSS (statistical package for social sciences) 22 
statistical package (SPSS Inc., Illinois, U.S.A). P value less than 0.05 was 
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taken as being significant. Results: The mean age of the pregnant women 
studied was 28.8 years ± 5.2 while the mean parity was 1.20 ± 1.16.  220 
pregnant women who came for antenatal booking were recruited into this 
study. Of these, 4.6% (n=10) were seropositive for hepatitis B surface antigen 
(HBsAg). Multiple sexual partners and Female circumcision were the 
significant risk factors for HBsAg seropositivity (p<0.05). There was no 
significant association with respect to a history of jaundice or contact with a 
jaundiced patient,  previous blood transfusion, intravenous drug abuse or 
sharing of sharps, previous surgery, episiotomies or dilatation and curettage 
(p>0.05). Conclusion: The intermediate endemicity of Hepatitis B virus 
infection in this study according to WHO classification, justifies the need for 
routine screening in pregnancy to identify and treat the infection accordingly 
as this will reduce the mother to child transmission. Multiple sexual partners 
and female circumcision are significant risk factors associated with Hepatitis 
B virus infection in this environment. Active and passive immunization to 
infants of HBsAg seropositive mothers is advocated. 
 
Keywords: Hepatitis B virus, Hepatitis B surface antigen, Hepatitis in 
pregnancy 
 
Introduction 
 According to the Centre for Disease Control and Prevention, 
“Hepatitis’’ means inflammation of the liver. The liver is a vital organ that 
processes nutrients, filters blood and fights infection. When a liver is inflamed 
or damaged, its function can be affected. 1 
 Historically, hepatitis B surface antigen (HBsAg) was formerly called 
Australia antigen because it was first described in the serum of an Australian 
aborigine in 1963.2,3  Okochi and Murakami 3 in 1968, discovered that the 
Australian antigen was related to type B Hepatitis. 
 The Hepatitis B virus (HBV) is the prototype member of the 
Hepadnaviridae (hepatotropic DNA virus) family.4,5 HBV virions are double-
stranded particles, 40 to 42 nm in diameter with an outer lipoprotein envelope 
that contains three related envelope glycoproteins (or surface antigens).5,6 
Within the envelope is the viral nucleo-capsid, or core. 6,7 
 Whereas Hepatitis may be caused by several viruses, it can also be 
caused by drugs or toxic chemicals with similar clinical manifestations of all 
forms. 4 
 Globally, more than 2 billion people have been infected with HBV at 
some time in their lives.8  In the past, it was estimated that over 350 million 
people were chronically infected worldwide and over 1 million die annually 
of HBV related chronic liver disease. 9 However, currently an estimated 240 
million people are chronically infected with Hepatitis B (defined as hepatitis 
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B surface antigen positive for at least 6 months) and more than 780, 000 people 
die annually due to complications of Hepatitis B, including liver cirrhosis and 
liver cancer. 10 Even with the decrease in the disease burden, globally it’s still 
a major public health problem. Adults infected with HBV usually acquire an 
acute Hepatitis B infection and recover without sequelae, but 5-10% 6 may 
develop the chronic carrier state. Infected children rarely develop acute 
disease, but 25 - 90% become chronic carriers. 11   Neonates who acquire 
hepatitis will have an almost  90% risk of developing chronic HBsAg carrier 
state and chronic liver disease. Infants may also spread the disease to siblings 
and to their community. 11 
 Transmission occurs when blood or body fluid of an infected person 
enters the body of a person who is not immune.12,13 In developing countries, 
the main routes of transmission are perinatal with Hepatitis B surface antigen 
(HBsAg) carrier mothers infecting their infants usually during birth. Other 
means of transmission are transfer of HBV through cuts, sexual transmission, 
transfusion of infected blood or blood products, needle stick injury, 
contamination of eye, re-use of HBV contaminated needles, syringes, lancets 
and instruments used in tribal markings, and possibly through blood sucking 
insects and bed bugs.14 
 Nigeria is classified among the group of countries endemic for HBV 
infection with a current infected population of 18 million.15 Despite the 
existence of a safe and effective vaccine, Nigeria has remained a hyper-
endemic area for HBV infection, with an estimated 12% of the population 
being chronic carriers. 16 
 In South South Nigeria, Akani et al17 in Port Harcourt reported a 
seroprevalence of 4.3% and also Aigere et al 18 in Irrua reported 6.8%. In South 
West Nigeria,  Agbede et al.,19  2007 reported 5.7% from Ilorin. 8.3% from 
Zaria in North west Nigeria (Luka et al., 2008) 20 and in North Central Nigeria, 
Mbaawuaga et al 21 reported 11% to mention but a  few. Consequently, studies 
on HBV infection in Nigeria have shown that the seroprevalence of the 
infection in pregnant women range from 3.8-13.3%. 16,22-28 
 Accepting, enshrining and implementing new policies and 
interventions by institutions, policy makers and administrators in resource or 
economically constrained countries must be evidence based  particularly so in 
urban areas where the pace is set for rural and suburban areas to follow. Also, 
being a new training or research centre in the region, no previous study has 
been done on the seroprevalence and clinico-epidemiological correlates of 
Hepatitis B surface antigen  in pregnancy at the Federal Medical Centre, 
Yenagoa. In view of these existing fact and the need to have a robust literature 
on viral Hepatitis in Africa, it’s of utmost importance to enable us reappraise 
our continued dependence on Western data, while we provide evidence based 
local data for policy making. 
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Objectives 
 The general objective is to determine the seroprevalence and clinico-
epidemiological correlates of Hepatitis B surface antigen  in pregnancy in 
Yenagoa.  
 The specific objectives are (1) To find out the seroprevalence of HBV 
in pregnant women that present in clinic. (2) To identify known risk factors 
for HBV infections in pregnant women. (3) To make evidence based 
recommendations on screening protocols for our obstetric population.  
 
Methodology 
Study Area 
 This study was carried out at the Antenatal clinic of the Federal 
Medical Centre, Yenagoa, Bayelsa state in the South-south region of Nigeria 
between  4th September to 28th October, 2016.  
 
Study design 
 A descriptive cross sectional study. 
 
Inclusion criteria 
 This included  all pregnant women who presented for booking at the 
antenatal clinic of FMC Yenagoa and  gave consent. 
 
Exclusion Criteria  
• This  included all pregnant women who declined to participate. 
• Patients who withheld their consent for inclusion in the study. 
• Those immunised within the last six (6) months 
 
Sample size  
 The sample size was calculated using the statistical formula 29 based 
on reported prevalence rates of hepatitis B of 13.3%16 from previous a study 
and a confidence interval of 95%.  
 
Study population  
 The minimum sample size was thus calculated to be 212 with an 
attrition of 20%. However, a total of 220 consecutive healthy pregnant women 
attending the antenatal booking clinic of the hospital who met the inclusion 
criteria were recruited into this study after pre test counselling and obtaining 
consent from them. This was tested for HBsAg. 
 
Sample collection and processing 
 Five millilitres (5ml) of peripheral venous blood was collected from 
consecutive subjects in the antenatal booking clinic into plain sterile bottles. 
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Blood samples were centrifuged for ten minutes at 6,000 rpm, serum was 
obtained and stored at -20OC until used. 
 Samples were analysed in batches with commercially available in vitro 
diagnostic kits (one step test strips). The HBsAg one step test is a rapid lateral 
flow immunoassay which qualitatively detects the presence of HBsAg in 
serum utilizing a combination of monoclonal and polyclonal antibodies to 
selectively detect elevated levels of HBsAg in serum. The membrane is 
percolated with anti- HBsAg antibodies on the test line region of the strip. 
During testing, the serum specimen reacts with the particles coated with anti- 
HBsAg antibody. The mixture migrates upward on the membrane 
chromatographically by capillary action to react with anti- HBsAg antibodies 
on the membrane and generate a coloured line in the test region.  
 To serve as procedural control, a coloured line always appeared at the 
control line region indicating that proper volume of specimen had been added 
and membrane wicking had occurred. Tests in which two distinct red lines 
appeared, one in the control region and another in the test region, was regarded 
as positive. Tests in which only the control line was distinctly coloured red 
was  recorded as negative while tests in which the control line fails to appear 
was regarded as invalid and was repeated. 
 Each sero-positive woman for HBsAg  had a liver enzyme assay done 
particularly the serum transaminases (alanine and aspartate transaminase), as 
these have been shown to increase in active liver disease. The Randox test kit 
by RANDOX Laboratories Ltd., United Kingdom was used (because this is 
the standard test kit being utilized by the hospital). Levels above 12 U/L were 
regarded as elevated for both AST and ALT.  
 
Questionnaire 
 Women were enrolled and underwent pretest counselling and were 
administered a structured interviewer- administered questionnaire. 
 
Data analysis 
 Data was analysed using SPSS (statistical package for social sciences) 
22 statistical package (SPSS Inc., Illinois, U.S.A). Univariate analysis for 
categorical variables was performed using chi-square. P value less than 0.05 
was taken as being significant. 
 
Ethical considerations 
 Approval for the study was obtained from the ethical committee of the 
Federal Medical Centre, Yenagoa. The study was carefully explained to the 
patients and their informed consent obtained before being recruited into the 
study. 
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Results 
 A total of two hundred and twenty (220) pregnant women were 
interviewed.  
 The predominant age group was 20-29 years (50.0%). The mean age 
is 28.8 years ± 5.2. Majority (50.0%) of the respondents were from the Ijaw 
ethnic group and it is followed closely by the Igbo ethnic group (28.2%). Most 
(96.8%) of the respondents were Christians.  Majority (41.8%) of the 
respondents were involved in doing business as an occupation. Majority 
(91.8%) also, of the respondents were married, and most of the marriages were 
of the polygamous type or setting (83.7%). Most (77.8%) had a secondary 
education.  
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Table 1: Awareness, risk factors/transmission mechanisms of Hepatitis B  viral infections. 
Variables                                                                                         Frequency (%)                                      Total 
                                                                                     Yes                   No        I don’t know 
Do you know about Hepatitis B infections?                                31 (14.6)        182 (85.4)    213 (100.0)                                                                                                                                                                                                                                    
Can this virus be transmitted from person to person                   29 (13.6)         1 (0.5)          186 (86.1)    216 (100.0) 
If yes, through which means 
Blood/blood products                                                                  15 (51.7)        0 (0) 
Body fluids-urine, saliva                                                               2 (6.9)          0 (0)  
Sexual intercourse                                                                        10 (34.5)       0 (0)   
Physical contact with infected person                                           2 (6.9)          0 (0)  
Total                                                                                             29 (100.0)     0 (0) 
Can these virus/infection be transmitted from mother  
to baby                                                                                         12 (5.5)          0 (0)              206 (94.5)     218 (100.0) 
If yes, when 
In utero                                                                                          2 (16.7)        0 (0) 
During delivery                      4 (33.3)         0 (0) 
Breastfeeding                      1 (8.3)           0 (0) 
I don’t know                                                                                 5 (41.7)        0 (0)  
Total                                                                                             12 (100.0)    0 (0) 
Have you had more than one sexual partner in your life            158 (72.5)      60 (27.4)                           218 (100.0) 
Does your husband have other sexual partners                            6 (2.8)        26 (12.0)      185 (85.3)      217 (100.0) 
Have you ever had sexually transmitted infections                     31 (14.1)     189 (85.9)                           220 (100.0) 
Have you ever had blood /blood product transfusion                  13 (6.0)       205 (94.0)                           218 (100.0) 
Do you share razor blades/needles with other people                   7 (3.2)       211 (96.8)                           218 (100.0) 
Have you ever engaged in injecting yourself with  
illicit(hard) drugs                                                                           3 (1.4)        216 (98.6)                          219 (100.0) 
 
 Only 31 (14.6%) of the respondents knew hepatitis B  infection. If this virus could be transmitted from person to 
person, 29 (13.6%) agreed that it could be transmitted from person to person; while 1 (0.5%) said no, that it could not be 
transmitted from person to person; and 186 (86.1%) did not know. Amongst those that agreed that the virus could be 
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transmitted from person to person, 15 (51.7 %) said it is through blood/blood 
products; while 10 (34.5%) said it is through sexual intercourse; and 2 (6.9%) 
said it is through body fluids- urine, saliva and physical contact with infected 
persons.  
 Twelve (5.5%) of the respondents said yes, that the virus could be 
transmitted from a mother to her baby, while 206 (94.5%) did not know if 
there could be transmission of the viruses from a mother to her baby. Amongst 
those that said yes, 4 (33.3%) said the infection occurs during delivery; while 
5 (41.7%) do not know how the transmission occurs; 2 (16.7%) said it occurs 
in-utero; and 1 (8.3%) said it occurs during breastfeeding. 
 Majority (72.6%) of the respondents has had more than one sexual 
partner in their life. Most (85.3%) of the respondents did not know if their 
spouses had other sexual partners. Eighty-five point nine percent (85.9%) said 
they have not had sexually transmitted infections in the past; and 94% of the 
respondents has not had transfusion of blood and blood products; 96.8% do 
not share needles/blades with other people; and 98.6% do not inject illicit 
drugs. 
Table 2: The seroprevalence of Hepatitis B  amongst the different parity groups. 
Variables                                                      Frequency (%)               
                                                                                                         
                                         Reactive                                                      Non reactive                  
Parity  
Para 0-1                             5 (50.0)                                                        118 (56.2)                              
Para 2-3                             3 (30.0)                                                         50 (23.8)                           
Para 4-5                             2 (20.0)                                                         23 (11.0)                           
Para 6-7                                0 (0)                                                            12 (5.7)                             
Para 8-9                                0 (0)                                                             7 (3.3)                             
Total                              10 (100.0)                                                      210 (100.0)                        
 
 From the table above, the mean parity is 1.20 ± 1.16. It was observed 
that respondents with parity of 0-1 had the highest 5 (50.0%) reactive HBsAg 
result; and had the highest prevalence of 50.0%.  
Table 3: The seroprevalence of Hepatitis B amongst the different Gestational Age groups. 
Variables                                               Frequency (%)                                                                  
                                                                                                                
                                  Reactive                                                    Non reactive                       
GA (In weeks) 
1 – 12                        4 (40.0)                                                         34 (16.2)                                
13– 24                       2 (20.0)                                                         89 (42.4)                              
25 - 40                       4 (40.0)                                                         87 (41.4)                              
Total                         10 (100.0)                                                    210 (100.0)                           
 
 Those respondents with a booking gestational age of between one 
week and twelve weeks (1 – 12), i.e. the first trimester; and those above twenty 
five weeks gestation i.e. those in third trimester gestation, were both found to 
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be 40.0% reactive to HBsAg. Hence, the prevalence of hepatitis B was equal 
in respondents of both the first trimester and third trimester. 
Table 4: The seroprevalence of Hepatitis B amongst those with history of abortion by 
Dilatation and Curettage. 
Variables                                                                      Frequency (%)                                                                  
                                                                                                                                         
                                                         Reactive                                               Non reactive               
History of abortion by D & C 
                                       Yes                0 (0)                                                        18 (8.5)                                                                                 
                                        No              10 (100.0)                                                192 (91.5)                       
Total                                                  10 (100.0)                                               210 (100.0)                      
 
 Amongst those that have carried out abortion by dilatation and 
curettage, none were reactive to HbsAg. 
 
Table 5: The relationship between having more than one sexual partner and the 
seroprevalence of Hepatitis B  infection. 
Variables                         Having more than one sexual partner             Total              Test/p -value 
                                         Yes (%)                          No (%) 
 HBsAg   
Reactive                       4 (40.0)                          6 (60.0)                        10 (4.6)            X2= 5.59 
Non- reactive              155 (74.2)                      54 (25.8)                     209 (95.4)          df = 1                
Total                          159 (72.6)                       60 (27.4)                    219 (100.0)        p<0.05 
 
The table above shows that there is a statistically significant association between respondents with more than 
one sexual partner and Seroprevalence of Hepatitis B Infection (P < 0.05). There was no association between 
respondents with more than one sexual partner.          
 
Table 6: The relationship between Circumcision and Seroprevalence of Hepatitis B viral infection. 
Variable                                        Circumcision                               Total             Test/p-value 
                                               Yes                          No           
 
 Reactive                                4 (40.0)                6 (60.0)                    10 (4.5)             X2 = 4.28 
 Non-reactive                         20 (9.5)             190 (90.5)                  210 (95.5)           df = 1 
Total                                      24 (10.9)           196 (89.1)                  220 (100.0)          p < 0.05      
The table above shows that there is a statistically significant association between respondents with female 
circumcision and prevalence of hepatitis B infection (p < 0.05). In other words, female genital circumcision 
in this study was found to be a significant risk factor to the development of hepatitis B infection. 
 
Table 7: The seroprevalence of Hepatitis B amongst those with history of tattoos/scarifications, and 
circumcision. 
 
Variables                                                                           Frequency (%)                                                                  
                                                                                                                                      
                                                                   Reactive                                           Non reactive    
___________________________________________________________________________________                  
Presence of tattoo/scarifications 
                        Yes                                         0 (0)                                                 2 (1.0)                                   
                        No                                        10 (100.0)                                        203 (99.0)                           
European Scientific Journal February 2018 edition Vol.14, No.6 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
288 
Total                                                            10 (100.0)                                       205 (100.0)                          
History of Circumcision 
                       Yes                                           4 (40.0)                                          19 (9.0)                            
                       No                                             6 (60.0)                                       191 (91.0)                           
Total                                                              10 (100.0)                                   210 (100.0)                          
 
 From the table above, there was zero percent reactive results for both 
HBsAg test  amongst the respondents that had tattoos/scarifications. 
Amongst those that were circumcised, 40.0% had positive HBsAg test. 
Table 8:  Relevant Clinical Parameters. 
Variables                                                                    Frequency (%)                      Total 
                                                                            Yes                             No 
Presence of jaundice                                       2 (0.9)                     214 (99.1)           216 
(100.0) 
Presence of right upper quadrant tenderness   2 (0.9)                    216 (99.1)           218 
(100.0) 
Presence of hepatomegaly                               2 (0.9)                     213 (99.1)          215 
(100.0) 
 
 Only 0.9% of the respondents agreed that they have had jaundice, right 
upper quadrant tenderness, and hepatomegaly in the past. 
Table 9: Results of Laboratory Investigations. 
Variables                                                              Frequency (%)                                   
Total 
                                                                Reactive                      Non reactive 
Result of HBsAg                                     10 (4.6)                        213 (96.8)             220 
(100.0) 
 
 
 Four point six percent (4.6%) of the respondents were reactive to 
HBsAg.  
 All HBsAg seropositive pregnant women had normal serum aspartate 
aminotransferase (AST: normal <12U/L), alanine aminotransferase (ALT: 
normal <12U/L), and alkaline phosphatase values (ALP: normal, 9-35U/L). 
 
Discussion 
 This is a hospital based study to determine the seroprevalence of 
HBsAg in an urban population of pregnant women and to evaluate the clinico-
epidemiological correlates of risk factors in this group. 
 The seroprevalence of HBsAg in our pregnant women population was 
4.6%. This means that our  pregnant women  have an intermediate endemicity  
for hepatitis B virus infection according to the WHO classification30. This is 
similar to what was reported in Port Harcourt17, Enugu26, Ilorin19 and Irrua 18 
which were 4.3%, 4.6%, 5.7% and 6.8% respectively. A higher prevalence rate 
of 8.3% and 11.6% were reported in Zaria20 and Maiduguri 31 respectively. A 
similar but slightly lower prevalence rate of 3.6% and 3.7% were reported 
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among a study population in Abuja and Ethiopia respectively 23,32. The 
prevalence in our study is however lower than the 12% in Taiwan or the 17.8% 
in Burkina Faso. 33,34 
 In this study, the seroprevalence of Hepatitis B was found to be highest 
amongst the 30 – 39 age group with 60.0% seroprevalence. There was a rise 
in the seroprevalence up to 39 years with an abrupt decline. Infection risks for 
Hepatitis B also increases with age naturally 35. This may be due to a greater 
probability of exposure of these women to risk factors with age. However, 
other studies have reported 20-24 age group from Irrua 18, Zaria 16 and Ethiopia 
32. This may have been due to the lower number of subjects in the much older 
age groups in their reports and perhaps the indulgence in high risk practices 
such as unprotected sexual intercourse and tattooing by the younger age 
groups in their environment. 
 Ijaw women had the highest seroprevalence rates. This is simply 
because majority (50.0%) of the subjects were from the Ijaw ethnic group 
which is the major ethnic group in this environs. The prevalence of HBsAg 
was more in nulliparous and primiparous females with a mean parity of 1.20 
± 1.16 in this study. This can be explained by the increased rate of multiple 
sexual partners (72.5%) in the past seen in our nulliparous and primiparous 
women as compared to our multiparous women. This finding was supported 
by Alegbeleye et al in Port Harcourt36. It is common reasoning that HBsAg  
prevalence would have been higher in multiparous women because of repeated 
risk of exposure to contaminated surfaces and instruments during delivery 
16,18,20. However, this was not the case in this study where the prevalence is 
higher in nulliparous and primiparous women. 
 The prevalence for HBsAg was highest in the first and third trimesters. 
This was comparable with findings by Aigere et al18 who observed that the 
third trimester in pregnant women had the highest prevalence rate. However, 
in this study, first trimester also topped the highest prevalence equally with 
third trimester. 
 Furthermore, in this study, notable risk factors such as intravenous 
drug use, blood transfusion, liver disease in our nulliparous and primiparous 
women respectively, were not associated with either HBV. None of the 
seropositive subjects had a history of blood transfusion. This may have been 
due to the aversion to receiving blood among our people. In Nigeria, illicit 
(hard) drugs including narcotics are strictly under control and attract severe 
sanctions thus limiting availability and or accessibility. This is why it’s not 
surprising that as low as 1.4% of the women alluded to have taken illicit drugs 
in this study. Also, the poor economic situation may preclude the majority of 
our women of reproductive age from having access to these drugs even if they 
will dare the law 27.  Tattooing/scarifications (0.9%) did not also contribute to 
HBsAg seropositivity. The cultural practice in this environment is on the 
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decline, as such it is not a surprising occurrence. Amongst the surgical risk 
factors, female circumcision(40%) even though a harmful traditional practice, 
posed a higher risk to HBsAg seropositivity than caesarean section (20%) and 
appendectomy (20%).  
 Previous studies have shown an inverse relationship between 
educational status and HbsAg positivity with less educated women showing 
the highest positivity.37,38,39  However, in this study, educational level was not 
found to statistically, significantly influence knowledge of hepatitis B 
infections (p > 0.05). Educational level was not also found to significantly 
influence both knowledge of virus/infection transmission from person to 
person and having more than one sexual partner in life (p > 0.05).  The reason 
may not be farfetched without any form of prejudice, unlike in the Northern 
part of the country where most of the women are uneducated, there are more 
educated women in this southern part of the country. This finding is similar to 
the study in Port Harcourt. 36 
 Majority (72.5%) of the obstetric women has had a history of multiple 
sexual partners in their life and in addition, most (85.3%) of them did not know 
if their spouses had other sexual partners. Of the HBsAg seropositive women, 
40% had history of multiple sexual partners and there was a significant 
association between the history of multiple sexual partners and seropositivity 
for HBsAg. There was a significant association between the history of multiple 
sexual partner and seropositivity for HBsAg. Dilatation and Curretage was not 
found to statistically, significantly influence Hepatitis B viral infections (p > 
0.05). This could be because most of the D and C was done in the hospital and 
the instruments used could have been well sterilized. These findings were 
similar to reports in Irrua 18. However, it was found in their study that 
Dilatation and curettage had a significant contribution to HBsAg 
seropositivity. 
 Previous screening reports show that universal prenatal screening for 
HBsAg is cost effective if the HBsAg carrier rate is greater than 0.06%.40 With 
a seroprevalence of 4.6%, the findings of this study affirmed the need for 
routine HBsAg screening among pregnant women in developing countries 
particularly in urban areas like Yenagoa for rural/suburban areas to mimic. 
 
Conclusion 
 The intermediate endemicity of Hepatitis B virus infection in this study 
according to WHO classification, justifies the need for routine screening in 
pregnancy and to treat the infection accordingly as this will reduce the mother 
to child transmission of the virus. Multiple sexual partners and female 
circumcision are significant risk factors associated with Hepatitis B virus 
infection in this environment. Active and passive immunization to infants of 
HBsAg seropositive mothers is advocated.  
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Recommendations 
• Sensitization and routine screening for Hepatitis B virus in pregnancy. 
• Treatment of Hepatitis B virus infection in pregnancy to reduce 
mother-to-child transmission. 
• Availability and accessibility of Hepatitis B immunoglobulin to babies 
born to HBsAg-positive mothers by Government and Non-
governmental organizations.  
• Sensitization and vaccination of adults against HBV especially those 
at risk e.g multiple sexual partners etc.  
• Campaign against Female Genital Mutilation. 
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